Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr Dreicer on the Different Approaches to mCRPC Management

April 18th 2024

Robert Dreicer, MD, discusses different approaches in prostate cancer management according to the type of oncologist.

Dr Guerra on a Culturally Tailored Approach to Prostate Cancer Screening Awareness

April 17th 2024

Carmen Guerra MD, MSCE, examines how a culturally sensitive could help raise prostate cancer screening awareness.

Dr Maxwell on a Study of Genetic Testing in Metastatic Prostate Cancer

April 17th 2024

Kara Maxwell, MD, PhD discusses a study of genetic testing results in metastatic prostate cancer.

Dr Piulats on Predictive Biomarkers for Treatment With Talazoparib/Enzalutamide in mCRPC

April 16th 2024

Josep Maria Piulats Rodriguez, MD, discusses an analysis evaluating predictive biomarkers for treatment with talazoparib plus enzalutamide in mCRPC.

Dr Koo on Challenges With PSMA PET in Prostate Cancer

April 12th 2024

Phillip J. Koo, MD, discusses the utility of next-generation imaging in prostate cancer, highlighting the use of PSMA PET in this patient population.

Dr Koo on the Clinical Utility of PSMA PET in Prostate Cancer

April 11th 2024

Phillip J. Koo, MD, discusses the clinical use of PSMA PET imaging in patients with prostate cancer.

PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC

April 10th 2024

FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.

Proteogenomic Signatures Shed Light on Prostate Cancer Recurrence Risk in Select Ancestries

April 10th 2024

A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors.

Patient Selection Key for Focal Therapy in Intermediate Prostate Cancer

April 5th 2024

Ruben Olivares, MD, discusses the integration of focal therapy in the treatment of patients with intermediate prostate cancer.

Koo Looks to the Future With PSMA PET Imaging in Prostate Cancer

April 4th 2024

Phillip J. Koo, MD, highlights future directions regarding PSMA PET imaging and key takeaways from a presentation he gave on the precision imaging tool.

Metastasis-Directed Radiotherapy Represents Significant Advancement in Prostate Cancer

April 4th 2024

Daniel Spratt, MD, discusses how evolving radiation therapy techniques in prostate cancer can reduce adverse effects and shorten treatment courses.

Recommendations Further Aid in Elucidating the Role of PSMA PET Imaging in Prostate Cancer

April 3rd 2024

Phillip J. Koo, MD, discusses how PSMA PET will be used in clinical trials, the RADAR VI guidelines for using the precision imaging tool, and more.

Dr Jha on Community Accrual to the ECLIPSE Trial in Prostate Cancer

April 3rd 2024

Gautam Jha, MD, discusses collaborative efforts between community and academic oncologists to accrue patients to the ECLIPSE trial.

Drs Antonarakis and Jha on Extending Clinical Trials to the Community Setting

April 3rd 2024

Emmanuel Antonarakis, MD, and Gautam Jha, MD, on collaboration efforts extending the reach of clinical trials beyond university hospitals.

Dr Spratt on Uncertainties Regarding Treatment Intensification in High-Risk Prostate Cancer

April 1st 2024

Daniel Spratt, MD, discusses ongoing debate and uncertainties regarding the optimal use of treatment intensification in high-risk prostate cancer.

Dr Knight on Diagnosing and Managing Brain-Metastatic Prostate Adenocarcinoma

March 29th 2024

James Knight, MD, discusses a case study of a patient with brain-metastatic prostate adenocarcinoma.

Dr Antonarakis on Community Enrollment in the ECLIPSE Trial in Prostate Cancer

March 29th 2024

Emmanuel Antonarakis, MD, discusses community enrollment in the ECLIPSE trial in prostate cancer.

Drs Jha and Antonarakis on Collaboration Between Community and Academic Oncologists

March 29th 2024

Gautam Jha, MD, and Emmanuel Antonarakis, MD, on the advantages of collaborative efforts between community and academic oncologists.

Dr Mehta on Radiation Oncology Innovations in Prostate Cancer

March 28th 2024

Minesh Mehta, MD, discusses recent advancements in radiation oncology approaches for patients with prostate cancer.

Dr Mehta on the Advantages of MRI-Guided Adaptive Radiotherapy in Cancer Care

March 26th 2024

Minesh Mehta, MD, discusses how MRI-guided adaptive radiation therapy systems may improve disease outcomes in cancer care.